Pharma BD Deal Intelligence
Too early to call: Lilly's up-to-$780M LimmaTech buy folds a Phase 1 S. aureus vaccine, LTB-SA7, into a $3.83B three-deal infectious-disease push — a bold diversification bet, though the lead asset has yet to clear even early clinical proof.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →LimmaTech Biologics AG, a Swiss clinical-stage biotech, will be acquired by Eli Lilly for next-generation vaccines against common bacterial infections.…
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals. Lilly announced agreements to acquire Curevo, LimmaTech Biologics and Vaccine…
Eli Lilly's Vaccine Acquisitions Signal a Strategy of Growth in New Areas. The three deals combined are valued at up to $3.83 billion and address viral…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Eli Lilly agreed to acquire Swiss bacterial-vaccine developer LimmaTech Biologics for up to $780M (cash upfront plus clinical/regulatory milestones). Lead program LTB-SA7 is in Phase 1 for Staphylococcus aureus surgical-site infection prevention; broader pipeline targets antimicrobial-resistant pathogens including Neisseria gonorrhoeae, Chlamydia trachomatis and Group B Streptococcus. Part of Lilly's three-deal infectious-disease vaccine push announced May 26.
56K US cases/yr · $2.0B Estimated peak US S. aureus vaccine TAM at modest penetration of high-risk surgical population (analyst estimates) · 45% Share of US S. aureus surgical-site infections that are methicillin-resistant (MRSA)
S. aureus is the leading cause of surgical-site infection (SSI), with an estimated 55,764 post-surgical S. aureus infections occurring annually in the US among 4.2 million elective inpatient surgical discharges. Approximately 45% are methicillin-resistant (MRSA). No licensed S. aureus vaccine exists despite decades of attempts. Broader LimmaTech pipeline targets antimicrobial-resistant pathogens including Neisseria gonorrhoeae and Chlamydia trachomatis where rising AMR is closing therapeutic options.
No licensed S. aureus vaccine exists; Pfizer's StaphVAX and Merck's V710 both failed Phase 3. Active developers include GSK (multivalent S. aureus vaccine), Vaxart, and academic consortia. LimmaTech's glycoconjugate approach targeting surface antigens and superantigens differentiates from prior failed protein-subunit attempts. The Lilly acquisition consolidates the leading remaining clinical-stage program with capital to fund Phase 2/3 development plus broader AMR pipeline optionality.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / LimmaTech Biologics AG (this deal) | 2026 | $780M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Infectious Disease deals